← Issue №10/ week of Sep 6, 2026/Colorectal

Delays in Diagnosis of Early-Onset Colorectal Cancer Across the United States: A Systematic Review.

From GI Signals issue №10: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Colorectal systematic review · Sep 1, 2026 · Dis Colon Rectum · IF 3.5

Delays in Diagnosis of Early-Onset Colorectal Cancer Across the United States: A Systematic Review.

Guideline / reviewepidemiologysystematic reviewhealth servicescolorectal cancer
Clinical takeawayMaintain a high index of suspicion for colorectal cancer in adults under 50 with persistent GI symptoms (e.g., rectal bleeding, change in bowel habits, abdominal pain), recognizing that diagnostic delays are common and stem from a combination of patient, provider, and system factors. Advocate for system-level interventions to support earlier detection.
What it foundThis systematic review of 35 studies on early-onset colorectal cancer found that most research uses advanced stage at diagnosis as a proxy for delay and identifies complex, crosscutting patient, provider, and system-level factors rather than a single quantifiable cause.
ContextThis review formalizes the widely recognized clinical problem of diagnostic delays in early-onset colorectal cancer, confirming that the issue is multifactorial and highlighting the limitations of the current evidence base, which often relies on stage at diagnosis as a proxy for delay. The findings emphasize the need for more qualitative research to identify effective interventions.
Measured against the standard of care· USMSTF 2017 (Rex et al., Gastroenterology) + USMSTF 2022 focused update on age (Patel et al., Gastroenterology 2022;162:285-299) / ACS 2026 (CA Cancer J Clin)

Decision at stakethe need for heightened awareness of early-onset colorectal cancer in patients under 45

… Multi-Society Task Force (2017 guideline, revised by the 2022 focused update on age to start and stop): offer average-risk colorectal cancer screening to everyone aged 45-75. … The American Cancer Society's May 2026 guideline agrees on the 45-75 range, no screening after 85, and colonoscopy as the preferred option. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

U.S. Multi-Society Task Force (2017 guideline, revised by the 2022 focused update on age to start and stop): offer average-risk colorectal cancer screening to everyone aged 45-75. Screening at 45-49 is a weaker recommendation than at 50-75. Colonoscopy every 10 years and annual FIT are the Tier 1 cornerstones. Tier 2 alternatives are multi-target stool DNA every 3 years, CT colonography every 5 years, and flexible sigmoidoscopy every 5-10 years. Capsule colonoscopy every 5 years is Tier 3. Any abnormal non-colonoscopy test requires a diagnostic colonoscopy, and a stool test should not be offered to a patient who would decline follow-up colonoscopy. Patients who are up to date with negative prior screening, particularly a high-quality colonoscopy, may consider stopping at 75 or when life expectancy is under 10 years. Decisions at 76-85 are individualized by health and prior screening, and screening after 85 is not recommended. The American Cancer Society's May 2026 guideline agrees on the 45-75 range, no screening after 85, and colonoscopy as the preferred option. It adds the next-generation mt-sDNA test and the multitarget stool RNA test (ColoSense), both every 3 years, and it adds an FDA-approved blood-based cfDNA test (Shield) only for people who decline or do not complete visual or stool screening. ACS says a positive stool or blood test should be followed by colonoscopy, preferably within 6 months. The 2026 ASGE paper on follow-up after an abnormal stool test is an implementation review (navigation, tracking, direct-access colonoscopy), not a new screening guideline.

USMSTF 2017 (Rex et al., Gastroenterology) + USMSTF 2022 focused update on age (Patel et al., Gastroenterology 2022;162:285-299) / ACS 2026 (CA Cancer J Clin) · reviewed 2026-10-11 ↗
Marzoughi M … Suwanabol PA · Diseases of the Colon and Rectum · IF 3.5 · PubMed ↗Permalink
← Read the whole of issue №10 Every paper GI Signals surfaces gets a page like this one. All issues